These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 17074440)

  • 1. Slow isomerization step in the interaction between mouse dopamine transporter and dopamine re-uptake inhibitor N-(3-iodoprop-2E-enyl)-2beta-carbo-[3H]methoxy-3beta-(4'-methylphenyl)nortropane.
    Stepanov V; Järv J
    Neurosci Lett; 2006 Dec; 410(3):218-21. PubMed ID: 17074440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of 3H-labeled N-(3-iodoprop-2E-enyl)-2beta-carbomethoxy-3beta-(4-methylphenyl)nortropane (PE2I) and its interaction with mice striatal membrane fragments.
    Stepanov V; Schou M; Järv J; Halldin C
    Appl Radiat Isot; 2007 Mar; 65(3):293-300. PubMed ID: 17081763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-(3-lodoprop-2E-enyl)-2beta-carbomethoxy-3beta-(3',4'-dichloro phenyl)nortropane (beta-CDIT), a tropane derivative: pharmacological characterization as a specific ligand for the dopamine transporter in the rodent brain.
    Garreau L; Emond P; Belzung C; Guilloteau D; Frangin Y; Besnard JC; Chalon S
    J Pharmacol Exp Ther; 1997 Jul; 282(1):467-74. PubMed ID: 9223589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characterisation of (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)nortropane (PE2I) binding to the rat neuronal dopamine transporter expressed in COS cells.
    Page G; Chalon S; Emond P; Maloteaux JM; Hermans E
    Neurochem Int; 2002 Feb; 40(2):105-13. PubMed ID: 11738476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetic mechanism of dopamine transporter interaction with 1-(2-(bis-(4-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)piperazine (GBR 12909).
    Stepanov V; Järv J
    Neurochem Int; 2008 Dec; 53(6-8):370-3. PubMed ID: 18845198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological characterization of (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)n ortropane as a selective and potent inhibitor of the neuronal dopamine transporter.
    Chalon S; Garreau L; Emond P; Zimmer L; Vilar MP; Besnard JC; Guilloteau D
    J Pharmacol Exp Ther; 1999 Nov; 291(2):648-54. PubMed ID: 10525084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, radiolabeling and preliminary in vivo evaluation of [18F]FE-PE2I, a new probe for the dopamine transporter.
    Schou M; Steiger C; Varrone A; Guilloteau D; Halldin C
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4843-5. PubMed ID: 19577467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and ligand binding of nortropane derivatives: N-substituted 2beta-carbomethoxy-3beta-(4'-iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2beta-carbomethoxy-3beta-(3',4'-disubstituted phenyl)nortropane. New high-affinity and selective compounds for the dopamine transporter.
    Emond P; Garreau L; Chalon S; Boazi M; Caillet M; Bricard J; Frangin Y; Mauclaire L; Besnard JC; Guilloteau D
    J Med Chem; 1997 Apr; 40(9):1366-72. PubMed ID: 9135033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetic analysis and quantification of the dopamine transporter in the nonhuman primate brain with 11C-PE2I and 18F-FE-PE2I.
    Varrone A; Tóth M; Steiger C; Takano A; Guilloteau D; Ichise M; Gulyás B; Halldin C
    J Nucl Med; 2011 Jan; 52(1):132-9. PubMed ID: 21189414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [11C]LBT-999: a suitable radioligand for investigation of extra-striatal dopamine transporter with PET.
    Saba W; Valette H; Schöllhorn-Peyronneau MA; Coulon C; Ottaviani M; Chalon S; Dolle F; Emond P; Halldin C; Helfenbein J; Madelmont JC; Deloye JB; Guilloteau D; Bottlaender M
    Synapse; 2007 Jan; 61(1):17-23. PubMed ID: 17068778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and in vivo evaluation of fluorine-18 and iodine-123 labeled 2beta-carbo(2-fluoroethoxy)-3beta-(4'-((Z)-2-iodoethenyl)phenyl)nortropane as a candidate serotonin transporter imaging agent.
    Plisson C; Stehouwer JS; Voll RJ; Howell L; Votaw JR; Owens MJ; Goodman MM
    J Med Chem; 2007 Sep; 50(19):4553-60. PubMed ID: 17705359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in interactions with the dopamine transporter as revealed by diminishment of Na(+) gradient and membrane potential: dopamine versus other substrates.
    Zhen J; Chen N; Reith ME
    Neuropharmacology; 2005 Nov; 49(6):769-79. PubMed ID: 16122767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological characterization of (E)-N-(4-fluorobut-2-enyl)-2beta-carbomethoxy-3beta-(4'-tolyl)nortropane (LBT-999) as a highly promising fluorinated ligand for the dopamine transporter.
    Chalon S; Hall H; Saba W; Garreau L; Dollé F; Halldin C; Emond P; Bottlaender M; Deloye JB; Helfenbein J; Madelmont JC; Bodard S; Mincheva Z; Besnard JC; Guilloteau D
    J Pharmacol Exp Ther; 2006 Apr; 317(1):147-52. PubMed ID: 16339913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-body distribution and radiation dosimetry of the dopamine transporter radioligand [(11)C]PE2I in healthy volunteers.
    Ribeiro MJ; Ricard M; Lièvre MA; Bourgeois S; Emond P; Gervais P; Dollé F; Syrota A
    Nucl Med Biol; 2007 May; 34(4):465-70. PubMed ID: 17499737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced expression and capacity of the striatal high-affinity choline transporter in hyperdopaminergic mice.
    Parikh V; Apparsundaram S; Kozak R; Richards JB; Sarter M
    Neuroscience; 2006 Aug; 141(1):379-89. PubMed ID: 16675138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I.
    Sasaki T; Ito H; Kimura Y; Arakawa R; Takano H; Seki C; Kodaka F; Fujie S; Takahata K; Nogami T; Suzuki M; Fujiwara H; Takahashi H; Nakao R; Fukumura T; Varrone A; Halldin C; Nishikawa T; Suhara T
    J Nucl Med; 2012 Jul; 53(7):1065-73. PubMed ID: 22689927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylphenidate analogs with behavioral differences interact differently with arginine residues on the dopamine transporter in rat striatum.
    Volz TJ; Bjorklund NL; Schenk JO
    Synapse; 2005 Sep; 57(3):175-8. PubMed ID: 15945061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploration of the dopamine transporter: in vitro and in vivo characterization of a high-affinity and high-specificity iodinated tropane derivative (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-m ethylph enyl)nortropane (PE2I).
    Guilloteau D; Emond P; Baulieu JL; Garreau L; Frangin Y; Pourcelot L; Mauclaire L; Besnard JC; Chalon S
    Nucl Med Biol; 1998 May; 25(4):331-7. PubMed ID: 9639293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo characterization of a novel phenylisothiocyanate tropane analog at monoamine transporters in rat brain.
    Murthy V; Martin TJ; Kim S; Davies HM; Childers SR
    J Pharmacol Exp Ther; 2008 Aug; 326(2):587-95. PubMed ID: 18492949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitive effects of Fructus Psoraleae extract on dopamine transporter and noradrenaline transporter.
    Zhao G; Li S; Qin GW; Fei J; Guo LH
    J Ethnopharmacol; 2007 Jul; 112(3):498-506. PubMed ID: 17555897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.